Reticular
Scaling Genomic AI for Embryo Selection
Based based in San Francisco, CA, USA, Reticular works in healthcare.
Profile
Reticular is scaling polygenic prediction for embryo selection, helping IVF couples plan their families today while building a platform to unlock cures for complex heritable diseases long-term.
John competed Biology Olympiads before spending 4 years at MIT publishing ML/bio research in NeurIPS and Nature. We believe biological models encode far more information than anyone is currently using - our goal is to unlock this potential.
The company sits in the healthcare segment, where it competes on its core product or service.
Its base of operations is San Francisco, CA, USA.
The company is listed at the Fall 2024 stage of development.
Its team size is recorded as 2 employees.
Directory analysis
Reticular develops a platform that applies genomic AI to predict polygenic traits in embryos, enabling IVF couples to make informed selection decisions. The company also aims to use the same technology to advance research into complex heritable diseases, combining machine learning with genomic data for actionable insights.
Positioning: Reticular operates at the intersection of reproductive technology and precision medicine, positioning itself in a niche yet rapidly evolving market. Its early‑stage focus on polygenic prediction could differentiate it if regulatory and data challenges are managed.
Note: Reticular is a small San Francisco‑based startup focused on AI‑driven embryo selection.
Auto-generated directory analysis from public data · updated 12 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 2 |
| Stage | Fall 2024 |
Website: reticular.com
Browse related
Create a free account